Kieran Lamb
Colin Ross is much better now he’s completed his first course of the drug Revlimid. As Dr Kevin Boyd, his specialist at the Royal Marsden hospital predicted, the drug is having a dramatic effect on Ross’s cancer, multiple myeloma. His paraprotein levels – which indicate the rate of spread of the disease – have come down from 67 to five, which his partner, Wendy Forbes-Newbigin, calls “little short of a miracle”.
UHN Health News Equity Ethics Financial Management Service Economics Private Sector Rationing Daily Mail
Would you like to comment?
Join Diigo for a free account, or sign in if you are already a member.